Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended June 30, 2004
Business Overview: BD is a medical technology company operating in three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2004 | Nine Months Ended June 30, 2004 |
|---|---|---|
| Revenues | $1,257.8 million | $3,727.8 million |
| Operating Income | $134.7 million | $534.4 million |
| Net Income | $109.4 million | $400.0 million |
| Diluted EPS | $0.41 | $1.51 |
| Gross Profit Margin | 50.4% | 48.9% |
| Cash from Operations (9mo) | $821.6 million | |
| Total Debt (Short + Long Term) | $1.155 billion | |
| Cash and Equivalents | $659.5 million | |
| Debt-to-Capitalization Ratio | 26.7% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8% for the quarter and 11% for the nine-month period compared to the prior year. Organic growth (excluding foreign currency) was approximately 5% for the quarter and 6% for the nine-month period.
- Profitability Impact: Net income decreased 16% for the quarter and increased 4% for the nine-month period. The decline in quarterly net income was primarily driven by a $100 million litigation settlement recorded in the third quarter.
- Segment Performance:
- Medical: Revenues up 5% (quarter) and 9% (nine months). Operating income impacted by $45 million in Blood Glucose Monitoring (BGM) charges recorded in the prior quarter.
- Diagnostics: Revenues up 11% (quarter) and 13% (nine months), driven by safety-engineered products and BD ProbeTec ET platforms.
- Biosciences: Revenues up 12% (quarter) and 15% (nine months). Operating income improved significantly compared to the prior year, which included $34 million in non-cash impairment charges.
- Balance Sheet: Short-term debt decreased significantly from $121.9 million to $6.1 million. Total debt-to-capitalization ratio improved to 26.7% from 30.4%.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects fiscal 2004 capital spending to be between $275 million and $300 million.
- Tax Rate: The effective tax rate for fiscal 2004 is expected to be approximately 23%.
- Strategic Focus: Growth is anticipated from core business expansion, global sales of high-quality products, and new product development with higher margins.
- Material Risks and Contingencies:
- Litigation: A $100 million settlement with Retractable Technologies, Inc. (RTI) was paid in July 2004. Other pending matters include patent litigation with Greiner and Therasense, and a qui tam lawsuit under the False Claims Act.
- Product Recalls: A voluntary recall of certain BGM test strips resulted in a $6.5 million reserve and inventory write-offs.
- Foreign Exchange: Results are subject to fluctuations in foreign currency exchange rates, particularly the Euro.
- Subsequent Event: On July 1, 2004, BD acquired Atto Bioscience, Inc. for approximately $25.3 million in cash.
Investor Verification Checklist
- Litigation Settlement: Verify the impact of the $100 million RTI settlement on cash flow and future legal exposure.
- BGM Charges: Confirm the status of the Blood Glucose Monitoring product line and the extent of inventory write-offs ($29.8 million) and recall reserves.
- Stock Repurchases: Review the $350 million in share repurchases during the nine-month period and the remaining authorization of 6.2 million shares.
- Foreign Currency Impact: Assess the difference between reported revenue growth and constant currency growth to understand organic performance.
- Acquisition Integration: Monitor the financial impact of the Atto Bioscience acquisition in the fourth quarter.